Prednisolone pharmacokinetics in asthmatic patients

May, C S; Caffin, Janet; Halliday, June W.; Bochner, Felix

doi:10.1016/0007-0971(80)90015-7

Cited by 7 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism for glucocorticoid resistance is not fully understood, although it has been extensively examined. In summary, the defect does not appear to be due to impaired bioavailablity of glucocorticoids (May et al 1980); the secretion of endogenous cortisol or sensitivity of the hypothalamic±pituitary±adrenal axis is not altered (Lane et al 1996); finally, no abnormalities in receptor nuclear translocation, density or binding affinity have been demonstrated (Lane & Lee 1991).…”

Section: Steroid Responsivenessmentioning

confidence: 91%

Personalised prescribing for asthma - is pharmacogenetics the answer?

Dewar

Hall

2003

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

An individual's response to anti-asthma medication is likely to arise from a complex interaction between social, environmental and inherited factors. Studies indicate that genetic factors may account for 60-80% of the heterogeneity in treatment responsiveness in asthmatics. Identifying the genetic variants responsible may potentially lead to the development of novel treatments, improved effectiveness in the use of existing treatments and better prediction of efficacy in phase II and III trials. This article will briefly outline the current methods of identifying relevant treatmentresponsive genes and their genetic variants. The pharmacogenetics of the main asthma treatment groups will then be reviewed in detail. Finally, the impact of pharmacogenetics on the pharmaceutical industry, and clinical practice in the future will be discussed.

show abstract

Section: Steroid Responsivenessmentioning

confidence: 91%